Patent ID: 7250430

Claim:
A method of treating a susceptible neoplasm selected from the group consisting of metastatic soft tissue sarcoma, non-small cell lung cancer, melanoma, ovarian cancer, breast cancer, leukemia, lymphoma, renal cancer, prostate cancer, and multiple myeloma in a mammal comprising administering to a mammal in need of such treatment an oncolytically effective amount of a compound of Formula I: where: —X═Y— is R 1 is selected from the group consisting of halo, C 1 -C 6 alkyl, and CF 3 ; R 2 is selected from the group consisting of halo, —NO 2 , C 1 -C 6 alkyl, and CF 3 ; R 3′ is H, C 1 -C 6 alkyl, C 1 -C 4 alkoxy, C 1 -C 6 alkylthio, or halo; R 4′ is selected from the group consisting of H, halo, C 1 -C 4 alkoxy, —COO(C 1 -C 6 alkyl), C 1 -C 6 alkyl optionally substituted with C 1 -C 4 alkoxy, cyano, C 1 -C 6 alkylthio, CF 3 , S-phenyl, and pyridinyl; R 5 is halo, C 1 -C 6 alkyl, or C 1 -C 4 alkoxy; or a pharmaceutically acceptable base addition salt thereof.